The clinical application of the immune checkpoint inhibitors (ICIs) that target PD-1, PD-L1, and CTLA-4 have shown significant and durable survival increases for a subset of patients with advanced NSCLC. However, the challenge in the usage of ICIs in lung cancer remains in understanding the biology of resistance, including predictive biomarkers beyond PD-L1 expression and the factors controlling either de novo or acquired resistance. The 2023 Hot Topic in Basic and Translational Science: Resistance to IO in NSCLC Conference includes new and emerging data on immunoresistance in NSCLC. Presentations will summarize information about ongoing clinical trials of the newest therapies for lung cancer including data on preclinical and early clinical data.

Session Topics:

• Epigenetic and Genomics Mechanisms of Resistance
• TME Contributors to Resistance
• Host Factors Associated with Resistance
• The Role of the Tumor Draining Lymph Node in Tumorigenesis and the Role of Tertiary Lymphoid Structures in Immune Resistance
• Vaccination to (Re)activate the Immune System
• Cell Therapy and T-Cell Engagers
• Big Data Discovery of Novel Resistance Mechanisms
• Resistance to Immune Checkpoint Blockade in the Clinic: Where are we Now?

Live Activity Dates: November 10-12, 2023
Location: Brussels, Belgium

This Meeting is geared towards researchers, clinicians, and students with the goal of expanding knowledge of the benefits of immunotherapy to a broader population of NSCLC patients. 

Upon completion of this activity, the participants should be able to:

• Understand current and emerging data on immunotherapy resistance in non-small cell lung cancer (NSCLC).
• Leverage mechanisms of immunotherapy resistance in lung cancer for therapeutic use.

Program Co-Chairs:

• Joachim Aerts, MD, PhD, Netherlands
• Roberto Ferrara, MD, Italy
• Kellie Smith, PhD, United States

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need assistance with this activity, please email: education@iaslc.org.